Sanofi and Regeneron Pharmaceuticals recently reported positive outcomes from a joint Phase 3 study of Dupixent (dupilumab) in addressing symptoms of moderate-to-severe atopic dermatitis, a form of eczema that presents as red, itchy skin and rashes.
The joint study assessed Dupixent’s impact on chronic itching, quality of life and anxiety and/or depression. Researchers found that patients reported a reduction of intensity and improved quality of life by nearly half after 16 weeks of treatment with Dupixent, a Sanofi release said.
Using the Eczema Area and Severity Index (EASI-75), researchers determined a mean improvement of at 59 to 63 percent for those treated with Dupixent, as compared with only 30 percent of patients given a placebo, the release said.
The study results were being presented at the European Academy of Dermatology and Venerology (EADV) Congress in Geneva, Switzerland, the release said.
“Dupixent with topical corticosteroids significantly improved overall measures of disease severity including lesions, itch, quality of life measures and symptoms of anxiety and depression in these patients,” Dr. Marjolein De Bruin-Weller, a dermatologist at the National Expertise Center for Atopic Dermatitis at the University Medical Center Utrecht, said in the release.
